Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2020232390 - THIAZOLIDINEDIONE COMPOUNDS FOR TREATMENT OF DRUG RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA

Publication Number WO/2020/232390
Publication Date 19.11.2020
International Application No. PCT/US2020/033230
International Filing Date 15.05.2020
IPC
A61K 31/4439 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 47/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
12Carboxylic acids; Salts or anhydrides thereof
A61K 31/425 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
CPC
A61K 31/426
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • WEST VIRGINIA UNIVERSITY [US]/[US]
Inventors
  • GELDENHUYS, Werner J.
  • GIBSON, Laura F.
  • NAIR, Rajesh R.
Agents
  • KRAMER, Terry
Priority Data
62/848,95016.05.2019US
63/024,92114.05.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) THIAZOLIDINEDIONE COMPOUNDS FOR TREATMENT OF DRUG RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
(FR) COMPOSÉS DE THIAZOLIDINÉDIONE POUR LE TRAITEMENT DE LA LEUCÉMIE LYMPHOBLASTIQUE AIGUË PHARMACORÉSISTANTE
Abstract
(EN) Cell death may be induced in a cancer cell line, by treating the cancer cell line with a compound of formula (I), a compound of formula (II), pharmaceutically acceptable salts thereof, mixtures thereof, enantiomers thereof, or racemates thereof: wherein X is a chacogen, e.g., O, S, or Se; NH; NR5, where R5 is a C1 to C8 alkyl group or a C1 to C8 acyl group; BR6, where R6 is a halogen, e.g., fluorine, bromine, or iodine, H, lower alkyl, or lower alkoxy; or Si(R7)2, where R7 is a C1 to C8 alkyl group or a C1 to C8 acyl group; and R1, R2, R3, and R4 are independently hydrogen, a C1 to C8 alkyl group, hydroxy, alkoxy, aryloxy, acyloxy, a thiol group, a thioalkyl group, a thioacyl group, an a sulfonamide group, an amino group, a mono- or dialkylamino group, an acylamino group, or a halogen.
(FR) La présente invention se rapporte à la mort cellulaire qui peut être induite dans une lignée de cellules cancéreuses, par traitement de la lignée de cellules cancéreuses avec un composé de formule (I), un composé de formule (II), des sels pharmaceutiquement acceptables, des mélanges, des énantiomères, ou des racémates de ceux-ci : X étant un chacogène, par exemple, O, S ou Se ; NR5, R5 étant un groupe alkyle en C1 à C8 ou un groupe acyle en C1 à C8 ; BR6, R6 étant un halogène, par exemple, le fluor, le brome ou l'iode, H, un alkyle inférieur ou un alcoxy inférieur ; ou Si(R7)2, R7 étant un groupe alkyle en C1 à C8 ou un groupe acyle en C1 à C8 ; et R1, R2, R3 et R4 étant indépendamment un atome d'hydrogène, un groupe alkyle en C1 à C8, un groupe hydroxy, alcoxy, aryloxy, acyloxy, un groupe thiol, un groupe thioalkyle, un groupe thioacyle, un groupe sulfonamide, un groupe amino, un groupe mono- ou dialkylamino, un groupe acylamino ou un halogène.
Latest bibliographic data on file with the International Bureau